Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.58 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.58 |
| ▸ | SMC2 | O95347 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.58 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.58 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18752892 | 0.91 | MAP2K1 (0.60) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL30746854 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL5741484 | 0.90 | MAP2K1 (0.58) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL1488195 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL30733259 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL27977753 | 0.89 | MAP2K1 (0.70) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL569289 | 0.83 | MAP2K1 (0.84) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL29461531 | 0.83 | MAP2K1 (0.84) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL22440178 | 0.83 | MAP2K1 (0.63) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL19141139 | 0.81 | MAP2K1 (0.52) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | claimed |
| EP-2130536-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | claimed |
| US-8193229-B2 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | claimed |
| US-7842816-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-20100267793-A1 | METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-10-21 | — | — | US | claimed |
| US-7777050-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-2130536-A1 | N3 alkylated benzimidazole derivatives as mek inhibitors | Array Biopharma, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| EP-1482932-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-11-25 | — | — | EP | claimed |
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | claimed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | claimed |
| JP-2007504139-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | claimed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | claimed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 164/4885MAP2K2 155/4885SMC2 3447/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MAP2K1 106/4885MAP2K2 108/4885SMC2 2986/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MAP2K1 164/4885MAP2K2 155/4885SMC2 3447/4885 |
| US-20100267793-A1 | METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | MAP3K19, BRAF, MAP3K9 | MAP2K1 134/4885MAP2K2 112/4885SMC2 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.